Want to join the conversation?
$PDCO 1Q16 Q&A: Robert Jones from Goldman Sachs asked about Sirona imaging system impacted equipment results. Scott said that it’s hard to quantify any pullback in the market. I would really say that would be one of the net catalysts going forward. There could be some reason of some delay, because of orthophos also.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.